These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
388 related articles for article (PubMed ID: 31123667)
1. Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives. Lu LC; Chang CJ; Hsu CH J Hepatocell Carcinoma; 2019; 6():71-84. PubMed ID: 31123667 [TBL] [Abstract][Full Text] [Related]
2. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma. Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862 [TBL] [Abstract][Full Text] [Related]
3. PPP1R15A-expressing monocytic MDSCs promote immunosuppressive liver microenvironment in fibrosis-associated hepatocellular carcinoma. Liu X; Liu M; Wu H; Tang W; Yang W; Chan TTH; Zhang L; Chen S; Xiong Z; Liang J; Wai-Yiu Si-Tou W; Shu T; Li J; Cao J; Zhong C; Sun H; Kwong TT; Leung HHW; Wong J; Bo-San Lai P; To KF; Xiang T; Jao-Yiu Sung J; Chan SL; Zhou J; Sze-Lok Cheng A JHEP Rep; 2024 Jul; 6(7):101087. PubMed ID: 38882672 [TBL] [Abstract][Full Text] [Related]
4. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic Values of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma: Facts and Hopes. Wang Y; Zhang T; Sun M; Ji X; Xie M; Huang W; Xia L Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680276 [TBL] [Abstract][Full Text] [Related]
7. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma. Wang X; Zhang Q; Zhou J; Xiao Z; Liu J; Deng S; Hong X; Huang W; Cai M; Guo Y; Huang J; Wang Y; Lin L; Zhu K J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36813307 [TBL] [Abstract][Full Text] [Related]
8. All-trans-retinoic acid inhibits hepatocellular carcinoma progression by targeting myeloid-derived suppressor cells and inhibiting angiogenesis. Li X; Luo X; Chen S; Chen J; Deng X; Zhong J; Wu H; Huang X; Wang C Int Immunopharmacol; 2023 Aug; 121():110413. PubMed ID: 37301119 [TBL] [Abstract][Full Text] [Related]
9. Siwu decoction suppress myeloid-derived suppressor cells through tumour cells necroptosis to inhibit hepatocellular carcinoma. Feng Z; Chan YT; Lu Y; Wu J; Xing T; Yuan H; Feng Y; Wang N Phytomedicine; 2024 Oct; 133():155913. PubMed ID: 39084183 [TBL] [Abstract][Full Text] [Related]
10. Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy. Wang Y; Jia A; Bi Y; Wang Y; Yang Q; Cao Y; Li Y; Liu G Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32942545 [TBL] [Abstract][Full Text] [Related]
11. The clinical and prognostic significance of CD14(+)HLA-DR(-/low) myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy. Wang D; An G; Xie S; Yao Y; Feng G Tumour Biol; 2016 Aug; 37(8):10427-33. PubMed ID: 26846107 [TBL] [Abstract][Full Text] [Related]
12. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Dysthe M; Parihar R Adv Exp Med Biol; 2020; 1224():117-140. PubMed ID: 32036608 [TBL] [Abstract][Full Text] [Related]
13. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells. Deng Y; Cheng J; Fu B; Liu W; Chen G; Zhang Q; Yang Y Oncogene; 2017 Feb; 36(8):1090-1101. PubMed ID: 27593937 [TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of targeting MDSCs in tumor microenvironment. Sui H; Dongye S; Liu X; Xu X; Wang L; Jin CQ; Yao M; Gong Z; Jiang D; Zhang K; Liu Y; Liu H; Jiang G; Su Y Front Immunol; 2022; 13():990463. PubMed ID: 36131911 [TBL] [Abstract][Full Text] [Related]
15. Circulating CD14 Gao XH; Tian L; Wu J; Ma XL; Zhang CY; Zhou Y; Sun YF; Hu B; Qiu SJ; Zhou J; Fan J; Guo W; Yang XR Hepatol Res; 2017 Sep; 47(10):1061-1071. PubMed ID: 27764536 [TBL] [Abstract][Full Text] [Related]
16. Visualization and quantification of Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525 [TBL] [Abstract][Full Text] [Related]
17. Activated hepatic stellate cells promote liver cancer by induction of myeloid-derived suppressor cells through cyclooxygenase-2. Xu Y; Zhao W; Xu J; Li J; Hong Z; Yin Z; Wang X Oncotarget; 2016 Feb; 7(8):8866-78. PubMed ID: 26758420 [TBL] [Abstract][Full Text] [Related]
18. Modulation of Immunosuppression by Oligonucleotide-Based Molecules and Small Molecules Targeting Myeloid-Derived Suppressor Cells. Lim J; Lee A; Lee HG; Lim JS Biomol Ther (Seoul); 2020 Jan; 28(1):1-17. PubMed ID: 31431006 [TBL] [Abstract][Full Text] [Related]
19. Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. Parker KH; Beury DW; Ostrand-Rosenberg S Adv Cancer Res; 2015; 128():95-139. PubMed ID: 26216631 [TBL] [Abstract][Full Text] [Related]
20. Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies. Wang S; Zhao X; Wu S; Cui D; Xu Z Biomark Res; 2023 Mar; 11(1):34. PubMed ID: 36978204 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]